Patent: 10,337,070

Summary for Patent: 10,337,070

Title:	Methods and kits for treating cardiovascular disease
Abstract:	The present invention relates, in part, to methods and kits for treating cardiovascular disease.
Inventor(s):	Kornman; Kenneth S. (Newton, MA), Doucette-Stamm; Lynn (Framingham, MA), Duff; Gordon W. (Sheffield, GB)
Assignee:	CardioForecast Ltd. (London, GB)
Application Number:	15/649,175
Patent Claims:	see list of patent claims

United States Patent 10,337,070: What the IL-1 SNP Panel Claim Covers and How Crowded the Landscape Is

What does US Patent 10,337,070 claim in operational terms?

US 10,337,070 claims a patient-selection and treatment method that combines (1) a defined multi-SNP “IL-1 genotype pattern” and (2) lipid biomarkers (LDL-C and/or Lp(a)) to diagnose “risk of a cardiac event,” followed by (3) administration of canakinumab (and optionally additional lipid-lowering or Lp(a)-targeted agents).

Claim 1: Stepwise method for IL-1-pattern selection + lipid threshold + canakinumab

Step (a): Obtain SNP allele information at five loci:

• rs16944
• rs1143623
• rs4848306
• rs17561
• rs1143634

Step (b): Determine the subject has a “positive IL-1 genotype pattern” if the subject’s five-locus genotype matches one of the enumerated IL-1 genotype patterns (i) through (xii).

• Each pattern is defined by specific permitted allele combinations at each locus.
• The patent’s claim language ties the selected genotypes to IL-1 biology without requiring expression assays.

Step (c): Obtain one or both plasma measurements:

• LDL-C (total)
• Lp(a) (total)

Step (d): Diagnose “at risk of a cardiac event” when:

• IL-1 genotype pattern is positive AND
• lipid threshold(s) are met:
  • LDL-C ≥ 50 mg/dL and/or
  • Lp(a) ≥ 5 mg/dL

Step (e): Administer canakinumab to reduce probability of a cardiac event.

Claim 2: Add-on lipid/Lp(a) therapies

Claim 2 adds that the method can further comprise administering one or more of:

• Evolocumab
• Alirocumab
• APO(a)-LᵣX
• ARC-LPA

What is novel in the claim mechanics (and what is not)?

The claim is not framed as a new monoclonal antibody. It is framed as a genotype-defined responder-identification method that gates canakinumab use based on an IL-1 multi-SNP panel and then confirms risk using LDL-C and/or Lp(a) thresholds.

What looks “novel” relative to prior art

1. Use of a specific five-SNP “IL-1 genotype pattern” as the gate for canakinumab treatment eligibility.
2. Combination of inflammatory genotype selection with lipid biomarker thresholds (LDL-C and/or Lp(a)) to support the “at risk” diagnosis.
3. Co-therapy language that includes specific lipid and Lp(a)-targeting agents (evolocumab, alirocumab, and investigational/construct therapies labeled as APO(a)-LᵣX and ARC-LPA in the claim text).

What is likely not novel

1. Canakinumab as an anti-inflammatory drug used to reduce cardiovascular events is not new as a concept, given its established testing history in cardiovascular outcomes contexts.
2. Lp(a) and LDL-C as cardiovascular risk biomarkers is not new.
3. Targeting inflammation in atherosclerotic risk is not new.

In other words, the patent attempts to pull novelty from patient stratification rules and the specific IL-1 genotype subset rather than from the pharmacology itself.

How strong are the claim elements against typical novelty/obviousness attacks?

This patent type usually lives or dies on whether the specific genotype panel and genotype-pattern matching were known and whether applying it to canakinumab in a cardiovascular event-prevention setting would have been obvious.

Element-by-element risk assessment

1) Five-locus SNP panel (rs16944, rs1143623, rs4848306, rs17561, rs1143634)

• A five-SNP panel is narrow relative to “any IL-1 SNP,” but still could be challenged if earlier publications, GWAS, or IL-1 pathway studies report these loci in relation to inflammation and/or cardiovascular risk.
• The claim does not require haplotype methods beyond allele matching. That can make it easier for examiners/courts to find prior disclosures that “teach” the same loci.

2) “Positive IL-1 genotype pattern” enumerated into 12 discrete genotype groups

• This enumeration can be a strength (specificity).
• It can also be a weakness if those exact genotype-pattern definitions are traceable to an earlier inventorship dataset or earlier publications describing “risk genotype combinations” for IL-1 pathway activity.

3) Lipid thresholds (LDL-C ≥ 50 mg/dL and/or Lp(a) ≥ 5 mg/dL)

• Thresholding is a frequent obviousness target. If earlier clinical literature uses these ranges to define “high risk,” an examiner may argue the lipid thresholds were standard risk gates.
• If there is no evidence those specific thresholds were selected for a mechanistic synergy with IL-1 genotype, the step (d) can be treated as routine confirmation.

4) Diagnosis statement + canakinumab administration

• Methods that end with “administer the drug” often face scrutiny under whether the “diagnosis” adds meaningful limitation beyond intended use.
• The claim is still a treatment method claim, and the genotype pattern and lipid thresholds are functional limitations, not mere language.

5) Co-administration with evolocumab, alirocumab, APO(a)-LᵣX, ARC-LPA

• Adding known monoclonals like PCSK9 inhibitors often increases obviousness risk because combination regimens are routine in lipid management.
• The “APO(a)-LᵣX” and “ARC-LPA” terms appear as specific therapy labels; if these were not widely disclosed at the time, that portion can shift novelty/obviousness differently than evolocumab/alirocumab.

Where does canakinumab fit in the cardiovascular inflammation patent and evidence ecosystem?

From a landscape perspective, canakinumab is entrenched in inflammation-cardiovascular trial history. That means a patent that uses canakinumab for event reduction is likely to face prior art overlap for general efficacy.

Therefore, the practical question for freedom-to-operate is not “can canakinumab reduce events?” It is whether the specific IL-1 multi-SNP selection rules and the specific lipid thresholds can be avoided, designed around, or invalidated.

Patent landscape impact: what will likely be the major blockers or overlap zones?

Because the claim ties directly to:

• IL-1 pathway genetics at specific rs-loci, and
• cardiovascular risk diagnosis, and
• canakinumab administration,

the highest density overlap zones typically include:

1) Inflammation-genetics and IL-1 pathway polymorphism patents

• Expect prior art on IL-1 gene polymorphisms and cardiovascular outcomes risk, including IL-1-related loci.
• Risk genotype-pattern panels are commonly patented when they are tied to a therapeutic decision.

2) Canakinumab cardiovascular treatment and patient selection patents

• Even if not using these exact SNPs, earlier canakinumab patents may claim patient stratification by inflammatory markers, hsCRP, IL-6, IL-1β pathway markers, or general high-risk profiles.
• If an earlier patent claims canakinumab for patients selected by inflammatory status, the remaining novelty would need to be the IL-1 SNP pattern.

3) Lipoprotein (a) and LDL-C stratification patents

• Risk thresholds and biomarker gating for cardiovascular treatment are heavily patented.
• The LDL-C ≥ 50 mg/dL and Lp(a) ≥ 5 mg/dL thresholds may overlap with guideline-based risk stratification or earlier patented cutoffs.

4) Combination therapy patents

• PCSK9 inhibitors are widely combined with other agents.
• Lp(a)-targeting agents and RNA-based approaches have a concentrated patent footprint.
• Claim 2’s optionality (“one or more of…”) increases the number of plausible overlap points.

Critical claim vulnerabilities likely to matter in enforcement or invalidation

A. Overbreadth on genotype-to-treatment causality

The claim does not establish mechanistic causality between each genotype combination and canakinumab response. It states that IL-1 genotype positivity plus lipid thresholds equals “at risk,” then administers canakinumab to reduce probability of a cardiac event.

That structure can be attacked as:

• insufficient nexus to a specific therapeutic effect for the genotype-defined subgroup, or
• “diagnostic label” that drives intended use rather than a technical feature.

B. Enumerated genotype patterns may be vulnerable if previously published

The 12 genotype-pattern sets are precise. Precision helps validity against generic prior art, but it can also hurt if those combinations already exist in:

• earlier genetic risk models,
• earlier IL-1 polymorphism panels,
• or earlier publications that connect these loci to cardiovascular risk or inflammatory pathways.

C. Lipid thresholds are likely to be treated as routine

LDL-C and Lp(a) gating is standard in cardiovascular risk. Threshold specificity can be attacked as obvious unless the patent provides a reason the thresholds align with IL-1 genotype-defined risk biology.

D. Combination therapy adds obviousness exposure

Claim 2 allows addition of evolocumab, alirocumab, and Lp(a)-targeting agents. Combination therapy is widely practiced, making claim 2 a likely obviousness magnet unless the IL-1 genotype requirement is treated as a unique non-routine driver.

Design-around pathways for competitors (what the claim structure allows them to avoid)

The claim is restrictive in specific ways, but competitors can still reduce exposure by altering at least one limiting feature:

Possible “avoidance lever”

1. Change the IL-1 genotype rule

   • If a product program uses a different IL-1 genetic pattern or omits one or more of the five loci, it may avoid matching the enumerated IL-1 genotype patterns.

2. Alter biomarker gating

   • The claim requires LDL-C and/or Lp(a) thresholds at:
     • LDL-C ≥ 50 mg/dL
     • Lp(a) ≥ 5 mg/dL
   • A different cutoff strategy or using additional/alternative biomarkers may reduce literal coverage.

3. Use a different anti-inflammatory agent

   • Claim 1 is specific to canakinumab. Substituting another IL-1 pathway therapy avoids the literal drug limitation.

4. Avoid “administer canakinumab” in the claimed patient group workflow

   • If the clinical decision does not follow the claimed steps in the same order (and the workflow is not equivalent), literal infringement can be harder.

What claim 2 does to infringement risk (and why it matters for combination trials)

Claim 2 adds optional co-administration with:

• Evolocumab
• Alirocumab
• APO(a)-LᵣX
• ARC-LPA

Because the add-on list is “one or more,” combination therapy trials may still fall within the claim even if they do not use all agents. The co-therapy language can matter because many real-world and trial protocols include PCSK9 inhibitors plus Lp(a) interventions.

If an investigational Lp(a) therapy program targets a genotype-gated IL-1 subgroup for canakinumab co-administration, claim 2 increases the chance of being dragged into the method claim.

How to read enforceability: the claim’s strongest and weakest points

Strongest points

• Specific loci and explicit genotype pattern sets.
• Drug specificity: canakinumab is named.
• Clear diagnostic criteria: IL-1 genotype positivity + LDL-C and/or Lp(a) thresholds.

Weakest points

• The genotype-to-disease linkage and genotype-to-canakinumab response linkage are asserted rather than tightly tied to a mechanistic technical outcome in the claim itself.
• Lipid thresholds are likely to be treated as conventional risk gating.
• Combination therapy language likely increases obviousness pressure.

Key Takeaways

• US 10,337,070 is a genotype-gated canakinumab method for cardiovascular event risk reduction, using five specified IL-1 pathway SNP loci and 12 enumerated “positive IL-1 genotype patterns.”
• The method then requires LDL-C ≥ 50 mg/dL and/or Lp(a) ≥ 5 mg/dL to diagnose “at risk,” and proceeds to canakinumab administration.
• Claim 2 expands coverage to combination regimens that can include evolocumab, alirocumab, APO(a)-LᵣX, and ARC-LPA, which elevates overlap with common lipid management trial designs.
• Enforcement and validity will likely hinge on whether the exact SNP loci/patterns and their use for cardiovascular risk gating in a canakinumab treatment decision are already disclosed or obvious from earlier work, and whether the lipid thresholds are treated as routine.

FAQs

1. Does the patent cover any IL-1 SNP panel?
   No. It is limited to allele determination at five specific rs loci and a match to one of the enumerated 12 IL-1 genotype patterns.

2. Is Lp(a) mandatory for diagnosis?
   No. The diagnosis can be based on LDL-C ≥ 50 mg/dL and/or Lp(a) ≥ 5 mg/dL.

3. Is canakinumab required in all methods?
   Yes. Claim 1 requires administration of canakinumab after the IL-1 genotype and lipid criteria are met.

4. Does Claim 2 require all listed add-on therapies?
   No. It says “one or more” of evolocumab, alirocumab, APO(a)-LᵣX, and ARC-LPA.

5. What is the most practical design-around lever?
   The most direct lever is to avoid the claimed IL-1 positive genotype pattern (loci/pattern matching) and/or to use a different biomarker gating framework that does not meet the specified thresholds.

---

References

[1] United States Patent 10,337,070, “Method of treating a human subject at risk of a future cardiac event…” (claims provided in prompt).

Details for Patent 10,337,070

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	June 17, 2009		2037-07-13
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	Injection	125319	December 22, 2016		2037-07-13
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015		2037-07-13
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016		2037-07-13
Regeneron Pharmaceuticals, Inc.	PRALUENT	alirocumab	Injection	125559	July 24, 2015		2037-07-13